Mark Henderson

Fusion raises US $25 million for cancer targeting technology

Mark Henderson
March 1, 2017

Fusion Pharmaceuticals Inc, a spin out of the Centre for Probe Development and Commercialization (CPDC), has secured US$25 million in series ‘A’ financing to support and accelerate development of new next-generation therapeutics that precisely target cancer cells.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics
Organizations: Centre for Probe Development and Commercialization, Centre of Excellence for Commercialization and Research, Fight Against Cancer Innovation Trust, Fusion Pharmaceuticals Inc, Genesys Capital, HealthCap, Johnson & Johnson Innovation, and TPG Biotechnology Ventures
Topics: Venture Capital

Other News

UHN receives $20-million gift from Daniels Foundation

OCE funds 20 IT-based automotive projects

York taps SIF for $113 million in facility upgrades

Hifi completes successful testing of O&G leak detection technology






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.